| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants (NCT06937619) | AbbVie | 2025-04-21 |
| A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants (NCT07566130) | AbbVie | 2025-04-18 |
| Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease (NCT06937034) | AbbVie | 2025-04-14 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) (NCT06858813) | AbbVie | 2025-04-14 |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis (NCT06865105) | AbbVie | 2025-04-11 |
| An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) (NCT06838845) | AbbVie | 2025-04-09 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants (NCT06895343) | AbbVie | 2025-04-03 |
| Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma (NCT06830759) | AbbVie | 2025-03-28 |
| A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (NCT06887010) | AbbVie | 2025-03-25 |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (NCT06772623) | AbbVie | 2025-03-06 |
| Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis (NCT06764706) | AbbVie | 2025-02-27 |
| A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (NCT06849791) | AbbVie | 2025-02-26 |
| A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (NCT06834789) | AbbVie | 2025-02-18 |
| A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years (NCT06810505) | AbbVie | 2025-02-13 |
| Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada (NCT06692881) | AbbVie | 2025-02-12 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma (NCT06822738) | AbbVie | 2025-02-11 |
| An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis (NCT06764693) | AbbVie | 2025-01-31 |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT06291220) | AbbVie | 2025-01-27 |
| A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants (NCT06794866) | AbbVie | 2025-01-22 |
| A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants (NCT06774313) | AbbVie | 2025-01-22 |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT06568939) | AbbVie | 2025-01-20 |
| Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (NCT06632951) | AbbVie | 2025-01-20 |
| A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (NCT06783621) | AbbVie | 2025-01-16 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma (NCT06667687) | AbbVie | 2025-01-16 |
| Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (NCT06701331) | AbbVie | 2024-12-22 |
| A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis (NCT06718101) | AbbVie | 2024-12-19 |
| A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants (NCT06742086) | AbbVie | 2024-12-19 |
| A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume (NCT06734351) | AbbVie | 2024-12-16 |
| A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (NCT06628310) | AbbVie | 2024-12-13 |
| A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers (NCT06078202) | AbbVie | 2024-12-01 |
| A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants (NCT06722417) | AbbVie | 2024-11-26 |
| Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (NCT06543914) | AbbVie | 2024-11-26 |
| A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants (NCT06722430) | AbbVie | 2024-11-13 |
| A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China (NCT06548568) | AbbVie | 2024-11-13 |
| Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting (NCT06639620) | AbbVie | 2024-11-12 |
| A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants (NCT06698926) | AbbVie | 2024-11-11 |
| A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer (NCT06614192) | AbbVie | 2024-11-08 |
| A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING (NCT06712628) | AbbVie | 2024-11-07 |
| Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants (NCT06575192) | AbbVie | 2024-11-05 |
| A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants (NCT06673238) | AbbVie | 2024-10-29 |
| A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder (NCT06618118) | AbbVie | 2024-10-23 |
| Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (NCT06605599) | AbbVie | 2024-10-15 |
| A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers (NCT06632938) | AbbVie | 2024-10-08 |
| A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine (NCT06602479) | AbbVie | 2024-10-07 |
| Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer (NCT06464692) | AbbVie | 2024-09-30 |
| Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium (NCT06581042) | AbbVie | 2024-09-27 |
| Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine (NCT06603558) | AbbVie | 2024-09-24 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (NCT06487559) | AbbVie | 2024-09-11 |
| A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants (NCT06571266) | AbbVie | 2024-09-11 |
| Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (NCT06417775) | AbbVie | 2024-09-10 |
| A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (NCT06579300) | AbbVie | 2024-09-04 |
| Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (NCT06548542) | AbbVie | 2024-09-04 |
| Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (NCT06300580) | AbbVie | 2024-08-21 |
| A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (NCT06461897) | AbbVie | 2024-08-19 |
| A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab (NCT06524635) | AbbVie | 2024-08-14 |
| Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease (NCT06332534) | AbbVie | 2024-08-08 |
| A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review (NCT06503536) | AbbVie | 2024-08-06 |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT06428019) | AbbVie | 2024-08-05 |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (NCT06365853) | AbbVie | 2024-07-29 |
| A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants (NCT06487572) | AbbVie | 2024-07-23 |
| A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality (NCT06547125) | AbbVie | 2024-07-18 |
| A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (NCT06477926) | AbbVie | 2024-07-09 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab (NCT06100744) | AbbVie | 2024-07-08 |
| Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease (NCT06459297) | AbbVie | 2024-06-24 |
| A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe (NCT06402513) | AbbVie | 2024-06-24 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT06223516) | AbbVie | 2024-06-17 |
| An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED) (NCT06443775) | AbbVie | 2024-06-17 |
| An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED) (NCT06439394) | AbbVie | 2024-06-17 |
| A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (NCT06389136) | AbbVie | 2024-06-14 |
| An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China (NCT06421740) | AbbVie | 2024-06-07 |
| Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein (NCT06093503) | AbbVie | 2024-05-31 |
| A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (NCT06390722) | AbbVie | 2024-05-23 |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT06158841) | AbbVie | 2024-05-19 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (NCT06414798) | AbbVie | 2024-05-13 |
| A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (NCT06333860) | AbbVie | 2024-05-10 |
| A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants (NCT06406348) | AbbVie | 2024-05-09 |
| A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants (NCT06399718) | AbbVie | 2024-04-30 |
| Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece (NCT06247319) | AbbVie | 2024-04-29 |
| A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants (NCT06345339) | AbbVie | 2024-04-26 |
| A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease (NCT06346288) | AbbVie | 2024-04-24 |
| A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence (NCT06387394) | AbbVie | 2024-04-22 |
| Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder (NCT06256367) | AbbVie | 2024-04-18 |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT06236438) | AbbVie | 2024-04-10 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (NCT06158854) | AbbVie | 2024-04-01 |
| A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines (NCT06308198) | AbbVie | 2024-03-29 |
| Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (NCT06241313) | AbbVie | 2024-03-25 |
| A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis (NCT06257875) | AbbVie | 2024-03-23 |
| A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer (NCT06318273) | AbbVie | 2024-03-08 |
| A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy (NCT06058741) | AbbVie | 2024-03-04 |
| A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration (NCT06278766) | AbbVie | 2024-02-21 |
| Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. (NCT05930275) | AbbVie | 2024-02-19 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors (NCT06158958) | AbbVie | 2024-02-06 |
| A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines (NCT06218251) | AbbVie | 2024-02-05 |
| A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants (NCT06148181) | AbbVie | 2024-01-29 |
| Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (NCT06107426) | AbbVie | 2024-01-24 |
| Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (NCT05956509) | AbbVie | 2024-01-12 |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (NCT06109272) | AbbVie | 2024-01-11 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China (NCT05821855) | AbbVie | 2024-01-09 |
| Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines (NCT06151561) | AbbVie | 2024-01-05 |
| A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) (NCT06058728) | AbbVie | 2023-12-20 |